Jazz Pharmaceuticals (JAZZ) Aktievy
Jazz Pharmaceuticals plc identifierar, utvecklar och marknadsför läkemedelsprodukter i USA, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 2/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
JAZZ Community Fair Values
Create NarrativeSee what 54 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Jazz Pharmaceuticals plc Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$248.70 |
| 52 veckors högsta | US$265.05 |
| 52 veckors lägsta | US$118.19 |
| Beta | 0.36 |
| 1 månads förändring | -2.17% |
| 3 månaders förändring | 3.70% |
| 1 års förändring | 106.34% |
| 3 års förändring | 79.22% |
| 5 års förändring | 87.05% |
| Förändring sedan börsintroduktionen | 1,302.71% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Aug 15
JAZZ: HER2 GEA Approval And Rare Epilepsy Deal Will Reshape Oncology Leadership
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals from $257.00 to $281.35, citing higher modeled revenue growth, stronger profit margins, and a richer future P/E assumption that reflect recent price target increases across the Street and confidence in the company's expanding oncology and rare-epilepsy portfolio. Analyst Commentary Street research on Jazz Pharmaceuticals has been active, with a cluster of higher price targets and fresh coverage reflecting updated views on execution, growth mix, and risk around key franchises and pipeline assets.Seeking Alpha • Aug 12
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Summary Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating. ABS-1230, with multiple FDA designations, could add $200–$400 million in peak sales if approved, I estimate, further strengthening JAZZ's epilepsy franchise. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Aug 15
JAZZ: HER2 GEA Approval And Rare Epilepsy Deal Will Reshape Oncology Leadership
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals from $257.00 to $281.35, citing higher modeled revenue growth, stronger profit margins, and a richer future P/E assumption that reflect recent price target increases across the Street and confidence in the company's expanding oncology and rare-epilepsy portfolio. Analyst Commentary Street research on Jazz Pharmaceuticals has been active, with a cluster of higher price targets and fresh coverage reflecting updated views on execution, growth mix, and risk around key franchises and pipeline assets.Seeking Alpha • Aug 12
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Summary Jazz Pharmaceuticals acquires Actio Biosciences for $820 million upfront, targeting rare KCNT1+ epilepsy with ABS-1230, a registrational-stage precision therapy. JAZZ delivered record Q2 2026 revenues of ~$1.2 billion, with strong year-on-year growth in key assets like Xywav (+13%) and Zepzelca (+42%). Despite a competitive narcolepsy landscape and $4.4 billion in debt, JAZZ's diversified portfolio, robust cash position, and M&A track record support a Buy rating. ABS-1230, with multiple FDA designations, could add $200–$400 million in peak sales if approved, I estimate, further strengthening JAZZ's epilepsy franchise. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 01
JAZZ: Ziihera Launch Expectations Will Drive Future Multiple Compression Risk
The analyst price target for Jazz Pharmaceuticals has moved higher, with the fair value estimate shifting from $205.58 to $212.63. This change is supported by analysts citing a greater focus on higher-value oncology products, updated views on Ziihera and other oncology launches, and ongoing management of sleep-franchise risks.Uppdatering av berättelse • Jul 18
JAZZ: Oncology Launch Execution Will Drive Future Multiple Compression Risk
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals slightly, from about $200.51 to $205.58. This change reflects updated assumptions around a shifting product mix toward oncology and a series of higher Street price targets tied to upcoming launches and sleep-franchise risk management.Uppdatering av berättelse • Jun 23
JAZZ: HER2 GEA Priority Review Will Support Future Oncology Leadership Narrative
Analysts have lifted the central analyst price target for Jazz Pharmaceuticals stock from $225.53 to $257.00, pointing to stronger conviction in Ziihera's potential uptake in gastroesophageal adenocarcinoma and biliary tract cancer, a firmer outlook for the oncology portfolio, and perceived resilience of the Xywav franchise. Analyst Commentary Recent research on Jazz Pharmaceuticals highlights a clear split between bullish analysts focused on Ziihera driven growth and oncology expansion, and more cautious voices focused on neurology concentration risk and competitive pressure.Analysartikel • Jun 18
Jazz Pharmaceuticals (JAZZ) Stock Could Be 73% Below Fair Value After Recent Pullback
Jazz Pharmaceuticals stock reaction puts recent performance in focus With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results. See our latest analysis for Jazz Pharmaceuticals. At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined...
Uppdatering av berättelse • Jun 06
JAZZ: Oncology Readouts And CNS Durability Will Support Future Upside Potential
Analysts have lifted their fair value estimate for Jazz Pharmaceuticals to $304.19 from $263.59, citing higher modeled revenue growth, stronger profit margins supported by views on Ziihera and zanidatamab, and confidence in Xywav patent protections that they argue could justify a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Jazz Pharmaceuticals presents a mixed but generally constructive tone, with several bullish analysts pointing to patent clarity on Xywav and the commercial opportunity for Ziihera and zanidatamab as key support pillars for their models.Uppdatering av berättelse • May 23
JAZZ: Oncology Execution Risks Will Drive Future Multiple Compression Concerns
Analysts have lifted the fair value estimate for Jazz Pharmaceuticals from $188.00 to about $200.51, citing a higher assumed future P/E multiple. They link this to growing confidence in the broader Ziihera and zanidatamab opportunities, even as they factor in slightly lower long term profit margins and ongoing competitive pressure on legacy neurology drugs.Analysartikel • May 13
We Think You Can Look Beyond Jazz Pharmaceuticals' (NASDAQ:JAZZ) Lackluster Earnings
The market was pleased with the recent earnings report from Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ), despite the...Analysartikel • May 08
Jazz Pharmaceuticals plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) investors will be delighted, with the company turning in some strong numbers...Uppdatering av berättelse • Apr 28
JAZZ: HER2 GEA Data Will Support Future Oncology Leadership Thesis
Analysts have nudged the price target on Jazz Pharmaceuticals higher to about $226, reflecting updated views on margins, central nervous system revenue durability, and upcoming oncology contributions following recent Q4 results and refreshed models. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has centered on refreshed models following Q4 results, updated revenue guidance, and the expected contribution from oncology assets alongside the core central nervous system portfolio.Uppdatering av berättelse • Apr 13
JAZZ: CNS Cash Flows And Upcoming Oncology Launches Will Shape Execution Risks
Analysts have increased their average price target on Jazz Pharmaceuticals by $13 to $255, citing more supportive assumptions around revenue growth, profit margins and a slightly lower future P/E following the recent Q4 results and updated guidance. Analyst Commentary Recent research on Jazz Pharmaceuticals has largely centered on updated price targets and ratings following the company’s Q4 report and new guidance.Uppdatering av berättelse • Mar 30
JAZZ: CNS Cash Flows And HER2 Franchise Will Shape Oncology Execution Risks
Narrative Update on Jazz Pharmaceuticals Analysts have lifted price targets on Jazz Pharmaceuticals by roughly $10 to $45 into a $224 to $275 range, citing steady central nervous system demand, updated Ziihera and zanidatamab expectations following HERIZON-GEA data, and recent Q4 results that aligned with or modestly exceeded prior forecasts. Analyst Commentary Recent research on Jazz Pharmaceuticals has been broadly constructive, with several firms adjusting price targets higher after Q4 results and the HERIZON GEA data updates.Uppdatering av berättelse • Mar 16
JAZZ: HER2 Data And CNS Cash Flows Will Balance Oncology Execution Risks
The analyst price target for Jazz Pharmaceuticals has been adjusted slightly higher to reflect a $1 increase in fair value to $188, lower modeled revenue growth at 2.92%, a higher profit margin assumption at 21.90%, and a reduced future P/E of 13.95, as analysts point to a resilient central nervous system franchise, updated views on Ziihera and zanidatamab opportunities, and recent Q4 results and guidance. Analyst Commentary Recent research coverage points to generally constructive sentiment on Jazz Pharmaceuticals, with a cluster of higher price targets anchored to the company’s central nervous system portfolio and oncology pipeline, including Ziihera and zanidatamab.Uppdatering av berättelse • Mar 02
JAZZ: Oncology Readouts And CNS Durability Will Drive Future Upside Potential
Our analyst fair value estimate for Jazz Pharmaceuticals has moved from $230.00 to about $263.59, as analysts factor in stronger margin expectations, a slightly higher discount rate, and ongoing Street enthusiasm around Ziihera and the broader oncology pipeline following recent Q4 updates and HERIZON-GEA data presentations. Analyst Commentary Recent Street research has leaned constructive on Jazz Pharmaceuticals, with multiple bullish analysts revisiting their models following Q4 results and the latest HERIZON-GEA data.Uppdatering av berättelse • Feb 16
JAZZ: HER2 Practice-Changing GEA Data Will Drive Future Oncology Leadership
Narrative Update Overview The analyst price target for Jazz Pharmaceuticals has moved higher, with our fair value estimate rising from $213 to $219.40 as analysts factor in stronger Ziihera and zanidatamab potential, supported by recent HERIZON-GEA data and updated Street research. Analyst Commentary Recent Street research on Jazz Pharmaceuticals has been largely constructive, with multiple firms updating their work after the detailed HERIZON-GEA-01 readout and related discussions around Ziihera and zanidatamab.Uppdatering av berättelse • Feb 02
JAZZ: Practice-Changing HER2 Data Will Drive Oncology Upside And Rebalance Legacy Risks
Analysts have raised their price targets on Jazz Pharmaceuticals by approximately $10 to $30 per share, citing what they describe as practice-changing HERIZON GEA data for Ziihera and a clearer oncology pipeline driver as key supports for the higher valuations. Analyst Commentary Across recent research notes, analysts have been revising their views on Jazz Pharmaceuticals primarily around the HERIZON GEA data for Ziihera and what it could mean for the oncology portfolio.Uppdatering av berättelse • Jan 19
JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks
Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.Uppdatering av berättelse • Jan 05
JAZZ: Oncology Data Will Reshape Revenue Mix While Legacy Headwinds Persist
We are raising our Jazz Pharmaceuticals fair value estimate to $188 from $147 as analysts boost price targets following positive HERIZON-GEA-01 data for Ziihera, which they see as a potential new standard of care and a multibillion dollar revenue driver. Analyst Commentary Street research following the HERIZON-GEA-01 topline readout has turned broadly constructive on Jazz Pharmaceuticals, with multiple firms lifting price targets and reiterating positive ratings.Uppdatering av berättelse • Dec 18
JAZZ: HER2-Positive GEA Breakthrough Will Drive Future Oncology Leadership
Analysts have nudged their fair value estimate for Jazz Pharmaceuticals higher to $213.00 from $208.50, reflecting stronger long term revenue growth expectations and a richer future P/E multiple, supported by increasingly bullish views on Ziihera's potential to become a new standard of care in HER2 positive GEA and a key oncology growth driver. Analyst Commentary Bullish analysts are largely focused on the upside from Ziihera's HERIZON-GEA-01 data, with multiple research shops lifting price targets and embedding higher long term oncology growth into their models.Uppdatering av berättelse • Dec 04
JAZZ: HER2-Positive GEA Success Will Drive Future Oncology Leadership And Upside
Our fair value estimate for Jazz Pharmaceuticals has nudged higher to $208.50 from $206.38, reflecting analysts' upward revisions to price targets as they factor in expectations of stronger long term revenue growth and profitability. This is driven by Ziihera's potential as a new standard of care in HER2 positive GEA and broader oncology indications.Uppdatering av berättelse • Nov 20
JAZZ: Recent Positive Trial Data Will Drive Future Leadership In HER2-Positive Oncology
Analysts have increased their price target for Jazz Pharmaceuticals from approximately $186 to $206 per share. They cite improved revenue growth projections and recent strong clinical data supporting the potential of Ziihera as a standard-of-care therapy in HER2-positive cancers.Analysartikel • Nov 18
Improved Revenues Required Before Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 25% Jump Looks Justified
Despite an already strong run, Jazz Pharmaceuticals plc ( NASDAQ:JAZZ ) shares have been powering on, with a gain of...Uppdatering av berättelse • Aug 30
Emerging Therapies And Portfolio Expansion Will Shape Future Markets
Analysts have modestly raised their price targets for Jazz Pharmaceuticals, driven by growing confidence in Modeyso's commercial prospects and expanded market potential, partially offset by persistent challenges in other segments, resulting in a new consensus target of $186.47. Analyst Commentary Bullish analysts are increasingly positive on the commercial potential of Modeyso following its recent approval, citing higher-than-expected pricing, a dedicated launch strategy, and strong patient/prescriber interest.Aktieägarnas avkastning
| JAZZ | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | 1.2% | 3.4% | -2.1% |
| 1Y | 106.3% | 54.6% | 18.8% |
Avkastning vs industri: JAZZ översteg US Pharmaceuticals branschen som gav 54.6 % under det senaste året.
Avkastning vs Marknaden: JAZZ översteg US marknaden som gav 18.8 % under det senaste året.
Prisvolatilitet
| JAZZ volatility | |
|---|---|
| JAZZ Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: JAZZ har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: JAZZ s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2003 | 2,890 | Renee Gala | www.jazzpharma.com |
Jazz Pharmaceuticals plc identifierar, utvecklar och marknadsför läkemedel i USA, Europa och internationellt. Företaget erbjuder Xywav för behandling av kataplexi eller överdriven dagtidssömnighet (EDS) vid narkolepsi och idiopatisk hypersomni (IH); Epidiolex för anfall i samband med Lennox-Gastauts syndrom (LGS), Dravets syndrom (DS) eller tuberös skleros (TSC); Rylaze för behandling av akut lymfoblastisk leukemi eller lymfoblastiskt lymfom; Enrylaze för behandling av akut lymfoblastisk leukemi och lymfoblastiskt lymfom; Zepzelca för behandling av metastaserad småcellig lungcancer där sjukdomen har fortskridit under eller efter platinabaserad kemoterapi; Ziihera för behandling av HER2-positiva cancerformer i gallvägarna; Modeyso för behandling av diffust midlinjegliom med en H3 K27M-mutation; samt Defitelio för behandling av svår veno-ocklusiv sjukdom. Företaget utvecklar även Zanidatamab i en fas 3-studie för behandling av HER2-positivt gastroesofagealt adenokarcinom (GEA) och cancer i gallvägarna (BTC); Dordaviprone för behandling av H3 K27M-mutant diffust gliom; samt Vyxeos för behandling av nydiagnostiserad behandlingsrelaterad akut myeloid leukemi.
Jazz Pharmaceuticals plc Sammanfattning av grunderna
| JAZZ grundläggande statistik | |
|---|---|
| Börsvärde | US$16.37b |
| Vinst(TTM) | US$940.75m |
| Intäkter(TTM) | US$4.60b |
17.2x
P/E-förhållande3.5x
P/S-förhållandeÄr JAZZ övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| JAZZ resultaträkning (TTM) | |
|---|---|
| Intäkter | US$4.60b |
| Kostnad för intäkter | US$397.85m |
| Bruttovinst | US$4.20b |
| Övriga kostnader | US$3.26b |
| Intäkter | US$940.75m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | 14.49 |
| Bruttomarginal | 91.35% |
| Nettovinstmarginal | 20.45% |
| Skuld/egenkapitalförhållande | 90.6% |
Hur har JAZZ utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/20 05:20 |
| Aktiekurs vid dagens slut | 2026/08/20 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Jazz Pharmaceuticals plc bevakas av 48 analytiker. 19 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Brian Skorney | Baird |
| Joel Beatty | Baird |
| null null | Baird |